Hypogonadism syndrome in men with inflammatory joint diseases: A review

Cover Page

Cite item

Full Text

Abstract

Most rheumatic diseases are characterized by sexual dimorphism both in prevalence and in the characteristics of the clinical course. Increased production of pro-inflammatory cytokines that accompanies inflammatory joint diseases may be accompanied by a decrease in the level of male sex hormones, and vice versa, the presence of hypogonadism in men increases the risk of developing certain rheumatic diseases. The review presents data on the relationship between testosterone deficiency and major inflammatory joint diseases, as well as the effect of testosterone replacement therapy on their manifestations.

About the authors

Taras S. Panevin

Nasonova Research Institute of Rheumatology

Author for correspondence.
Email: tarasel@list.ru
ORCID iD: 0000-0002-5290-156X

кандидат медицинских наук, научный сотрудник лаборатории эволюции ревматоидного артрита, врач-эндокринолог

Russian Federation, Moscow

Roman V. Rozhivanov

National Medical Research Center for Endocrinology

Email: tarasel@list.ru
ORCID iD: 0000-0002-5386-4289
Russian Federation, Moscow

Evgeny L. Nasonov

Nasonova Research Institute of Rheumatology

Email: tarasel@list.ru
ORCID iD: 0000-0002-1598-8360

академик РАН, доктор медицинских наук, профессор, научный руководитель

Russian Federation, Moscow

References

  1. Liegibel UM, Sommer U, Boercsoek I, et al. Androgen receptor isoforms AR-A and AR-B display functional differences in cultured human bone cells and genital skin fibroblasts. Steroids. 2003;68(14):1179-87. doi: 10.1016/j.steroids.2003.08.016
  2. Walker WH. Non-classical actions of testosterone and spermatogenesis. Philos Trans R Soc Lond B Biol Sci. 2010;365(1546):1557-69. doi: 10.1098/rstb.2009.0258
  3. Паневин Т.С. Влияние тестостерона на пуриновый обмен и подагру. Андрология и генитальная хирургия. 2021;22(3):11-7 [Panevin TS. Influence of testosterone on purine metabolism and gout. Andrology and Genital Surgery. 2021;22(3):11-7 (in Russian)]. doi: 10.17650/1726-9784-2021-22-3-11-17
  4. Rettew JA, Huet-Hudson YM, Marriott I. Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity. Biol Reprod. 2008;78(3):432-7. doi: 10.1095/biolreprod.107.063545
  5. Corcoran MP, Meydani M, Lichtenstein AH, et al. Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women. J Endocrinol. 2010;206(2):217-24. doi: 10.1677/JOE-10-0057
  6. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89(7):3313-8. doi: 10.1210/jc.2003-031069
  7. Torres-Chávez KE, Sanfins JM, Clemente-Napimoga JT, et al. Effect of gonadal steroid hormones on formalin-induced temporomandibular joint inflammation. Eur J Pain. 2012;16(2):204-16. doi: 10.1016/j.ejpain.2011.06.007
  8. Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., и др. Проект клинических рекомендаций «Синдром гипогонадизма у мужчин». Ожирение и метаболизм. 2021;18(4):496-507 [Dedov II, Mokrysheva NG, Melnichenko GA, et al. Draft of Russian clinical practice guidelines “Male hypogonadism”. Obesity and Metabolism. 2021;18(4):496-507 (in Russian)]. doi: 10.14341/omet12817
  9. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. J Androl. 2008;30(1):1-9. doi: 10.2164/jandrol.108.006486
  10. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl. 2009;32(6):587-98. doi: 10.1111/j.1365-2605.2008.00951.x
  11. Al Hayek A, Ajlouni K, Khader Y, et al. Prevalence of low testosterone levels in men with type 2 diabetes mellitus: a cross-sectional study. J Family Community Med. 2013;20(3):179-86. doi: 10.4103/2230-8229.122006
  12. Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest. 2016;39(9):967-81. doi: 10.1007/s40618-016-0480-2
  13. Garbagnati E, Boschetti M. Uric acid homeostasis in lean and obese girls during pubertal development. Metabolism. 1994;43(7):819-21. doi: 10.1016/0026-0495(94)90260-7
  14. Doghramji PP, Wortmann RL. Hyperuricemia and gout: new concepts in diagnosis and management. Postgrad Med. 2012;124:98-109. doi: 10.3810/pgm.2012.11.2616
  15. Stamp LK, Wells JE, Pitama S, et al. Hyperuricaemia and gout in New Zealand rural and urban Māori and non-Māori communities. Int Med J. 2013;43(6):678-84. doi: 10.1111/imj.12062
  16. Pizzichini M, Di Stefano A, Resconi G, et al. Influence of testosterone on purine nucleotide turnover in rat kidney. Horm Metab Res.1990;22:334-8. doi: 10.1055/s-2007-1004914
  17. Marinello E, Leoncini R, Terzuoli L, et al. Effect of testosterone on purine nucleotide metabolism in rat liver. Horm Metab Res. 2004;36:614-9. doi: 10.1055/s-2007-1004914
  18. Condorelli RA, Calogero AE, Di Mauro M, et al. Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index. J Endocrinol Investig. 2018;41:383-8. doi: 10.1007/s40618-017-0762-3
  19. Mu L, Pan J, Yang L, et al. Association between the prevalence of hyperuricemia and reproductive hormones in polycystic ovary syndrome. Reprod Biol Endocrinol. 2018;16(1):104. doi: 10.1186/s12958-018-0419-x
  20. Pui K, Waddell C, Dalbeth N. Early onset of hyperuricaemia and gout following treatment for female to male gender reassignment. Rheumatology (Oxford). 2008;47(12):1840-1. doi: 10.1093/rheumatology/ken391
  21. Kurahashi H, Watanabe M, Sugimoto M, et al. Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder. Endocr J. 2013;60(12):1321-7. doi: 10.1507/endocrj.ej13-0203
  22. Ebert T, Jockenhövel F, Morales A, Shabsigh R. The Current Status of Therapy for Symptomatic Late-Onset Hypogonadism with Transdermal Testosterone Gel. Eur Urol. 2005;47(2):137-46. doi: 10.1016/j.eururo.2004.09.015
  23. Cao W, Zheng R-D, Xu S-H, et al. Association between Sex Hormone and Blood Uric Acid in Male Patients with Type 2 Diabetes. Int J Endocrinol. 2017;2017:4375253. doi: 10.1155/2017/4375253
  24. He Y, Yang Q, Qing Y. Altered expression of androgen and its receptor might be involved in the pathogenesis of primary gouty arthritis. Gout and Hyperuricemia. 2015;2(2):56-61. doi: 10.3966/GH1506020203
  25. Lim JH, Kim Y-K, Kim Y-S, et al. Relationship Between Serum Uric Acid Levels, Metabolic Syndrome, and Arterial Stiffness in Korean. Korean Circ J. 2010;40(7):314-20. doi: 10.4070/kcj.2010.40.7.314
  26. Tong G, Hua X, Zhong Y, et al. Intensive insulin therapy increases sex hormone-binding globulin in newly diagnosed type 2 diabetic patients. Eur J Endocrinol. 2014;170(2):237-45. doi: 10.1530/eje-13-0557
  27. Kuczera P, Adamczak M, Wiecek A. Endocrine Abnormalities in Patients with Chronic Kidney Disease. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(2):109-18. doi: 10.1515/prilozi-2015-0059
  28. Mukhin IV, Ignatenko GA, Nikolenko VY. Dyshormonal disorders in gout: experimental and clinical studies. Bull Exp Biol Med. 2002;133:491-3. doi: 10.1023/a:1019826107916
  29. Marinello E, Riario-Sforza G, Marcolongo R. Plasma follicle-stimulating hormone, luteinizing hormone, and sex hormones in patients with gout. Arthritis Rheum. 1985;28(2):127-31. doi: 10.1002/art.1780280203
  30. Baillargeon J, Al Snih S, Raji MA, et al. Hypogonadism and the risk of rheumatic autoimmune disease. Clin Rheumatol. 2016;35(12):2983-7. doi: 10.1007/s10067-016-3330-x
  31. Pikwer M, Giwercman A, Bergstrom U, et al. Association between testosterone levels and risk of future rheumatoid arthritis in men: a population-based case-control study. Ann Rheum Dis. 2014;73:573-9. doi: 10.1136/annrheumdis-2012-202781
  32. Yang DD, Krasnova A, Nead KT, et al. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Ann Oncol. 2018;29(2):386-91. doi: 10.1093/annonc/mdx744
  33. Forslind K, Hafström I, Ahlmén M, Svensson B; BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis. 2007;66(1):46-52. doi: 10.1136/ard.2006.056937
  34. Прокаева Т.Б. Ревматоидный артрит у мужчин: автореф. дис. ... кандидат мед. наук. М., 1991 [Prokaeva TB. Revmatoidnyi artrit u muzhchin: avtoref. dis. ... kand. med. nauk. Moscow, 1991 (in Russian)].
  35. Tengstrand B, Carlström K, Hafström I. Bioavailable testosterone in men with rheumatoid arthritis-high frequency of hypogonadism. Rheumatology (Oxford). 2002;41(3):285-9. doi: 10.1093/rheumatology/41.3.285
  36. Gordon D, Beastall GH, Thomson JA, Sturrock RD. Prolonged hypogonadism in male patients with rheumatoid arthritis during flares in disease activity. Br J Rheumatol. 1988;27(6):440-4. doi: 10.1093/rheumatology/27.6.440
  37. Cutolo M, Balleari E, Giusti M, et al. Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum. 1991;34(1):1-5. doi: 10.1002/art.1780340102
  38. Tengstrand B, Carlström K, Hafström I. Gonadal hormones in men with rheumatoid arthritis – from onset through 2 years. J Rheumatol. 2009;36(5):887-92. doi: 10.3899/jrheum.080558
  39. Cutolo M, Sulli A, Capellino S, et al. Anti-TNF and sex hormones. Ann N Y Acad Sci. 2006;1069:391-400. doi: 10.1196/annals.1351.037
  40. Кондрашов А.А., Шостак Н.А. Композиционный состав тела у больных ревматоидным артритом мужского пола с учетом андрогенного статуса. Научно-практическая ревматология. 2021;59(6):700-7 [Kondrashov AA, Shostak NA. Composition of the body in male patients with rheumatoid arthritis with account of androgenic status. Rheumatology Science and Practice. 2021;59(6):700-7 (in Russian)]. doi: 10.47360/1995-4484-2021-700-707
  41. Straub RH, Härle P, Sarzi-Puttini P, Cutolo M. Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinflammatory action. Arthritis Rheum. 2006;54(7):2039-46. doi: 10.1002/art.21946
  42. Cutolo M, Seriolo B, Villaggio B, et al. Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Ann N Y Acad Sci. 2002;966:131-42. doi: 10.1111/j.1749-6632.2002.tb04210
  43. Ивахненко О.И., Дубинина Т.В., Коротаева Т.В., Лила А.М. Клинико-экономическая оценка применения генно-инженерных биологических препаратов и таргетных синтетических препаратов при анкилозирующем спондилите в условиях системы здравоохранения Российской Федерации. Современная ревматология. 2022;16(4):46-56 [Ivakhnenko OI, Dubinina TV, Korotaeva TV, Lila A.M. Clinical and economic evaluation of the use of biologic disease-modifying antirheumatic drugs and targeted synthetic antirheumatic drugs for ankylosing spondylitis in context of the Russian healthcare system. Modern Rheumatology Journal. 2022;16(4):46-56 (in Russian)]. doi: 10.14412/1996-7012-2022-4-46-56
  44. Perez-Garcia LF, Te Winkel B, Carrizales JP, et al. Sexual function and reproduction can be impaired in men with rheumatic diseases: A systematic review. Semin Arthritis Rheum. 2020;50(3):557-73. doi: 10.1016/j.semarthrit.2020.02.002
  45. Melillo N, Corrado A, Quarta L, et al. Psoriatic arthritis and Klinefelter syndrome: case report. Clin Rheumatol. 2007;26(3):443-4. doi: 10.1007/s10067-005-0153-6
  46. Ramonda R, Foresta C, Ortolan A, et al. Influence of tumor necrosis factor α inhibitors on testicular function and semen in spondyloarthritis patients. Fertil Steril. 2014;101(2):359-65. doi: 10.1016/j.fertnstert.2013.10.048
  47. Almeida BP, Saad CG, Souza FH, et al. Testicular Sertoli cell function in ankylosing spondylitis. Clin Rheumatol. 2013;32(7):1075-9. doi: 10.1007/s10067-013-2215-5
  48. McNeilly AS. Diagnostic applications for inhibin and activins. Mol Cell Endocrinol. 2012;359(1-2):121-5. doi: 10.1016/j.mce.2011.06.017.

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies